Regulation of gene expression through processing and turnover of RNA is a key mechanism that allows bacteria to rapidly adapt to changing environmental conditions. Consequently, RNA degrading enzymes (ribonucleases; RNases) such as the endoribonuclease RNase e, frequently play critical roles in pathogenic bacterial virulence and are potential antibacterial targets. RNase e consists of a highly conserved catalytic domain and a variable non-catalytic domain that functions as the structural scaffold for the multienzyme degradosome complex. Despite conservation of the catalytic domain, a recent study identified differences in the response of RNase E homologues from different species to the same inhibitory compound(s). While RNase e from Escherichia coli has been well-characterised, far less is known about RNase e homologues from other bacterial species. In this study, we structurally and biochemically characterise the RNase e catalytic domains from four pathogenic bacteria: Yersinia pestis, Francisella tularensis, Burkholderia pseudomallei and Acinetobacter baumannii, with a view to exploiting RNase e as an antibacterial target. Bioinformatics, small-angle x-ray scattering and biochemical RNA cleavage assays reveal globally similar structural and catalytic properties. surprisingly, subtle species-specific differences in both structure and substrate specificity were also identified that may be important for the development of effective antibacterial drugs targeting RNase E.
In silico structural analysis of the RNase e NtDs. In order to begin to investigate whether the amino acid sequence similarity also correlates with structural similarity, we decided to generate homology models for YpRNase E, FtRNase E, BpRNase E and AbRNase E NTDs using available EcRNase E NTD crystal structures as templates. The crystal structure of EcRNase E NTD has been solved in the presence 18, 25 and absence 26 of RNA substrates and collectively these structures suggest a large conformational change between an open and closed conformation upon substrate binding 26 . Both open and closed conformation homology models were generated using the EcRNase E NTD crystal structures 2VMK 26 and 2BX2 18 as the template structure, respectively (Fig. 2) . Globally, the homology models are very similar to the EcRNase E NTD crystal structures and this is reflected in the low root-mean-square deviation (RMSD) obtained for each model compared to the template crystal structure (Fig. 2) . Even regions that are poorly conserved at the sequence level (e.g. amino acids 175-203 of the 5′ sensor, 233-263 of the RNase H domain and 457-508 of the small domain ( Fig. 1) ) are predicted to adopt a similar conformation ( Fig. 2; Supplementary Fig. 2 ). The RMSDs for the homology models generated using the closed EcRNase E NTD crystal structure 2BX2 18 as a template are slightly lower than those generated using the open EcRNase E NTD structure 2VMK 26 as the template. However, this most likely reflects the higher resolution of the closed structure (2.85 Å) 18 compared to the open structure (3.3 Å) 26 . Overall, these data suggest that YpRNase E, FtRNase E, BpRNase E and AbRNase E NTDs are likely to fold into a similar structure and adopt similar conformations to EcRNase E NTD. This also implies that the conformational change from open to closed proposed for EcRNase E 26 is, at least theoretically, possible.
Purification of recombinant RNase E NTDs. In order to structurally and functionally characterise
YpRNase E, FtRNase E, BpRNase E and AbRNase E NTDs, and compare their properties to those of EcRNase E NTD, pure recombinant RNase E NTDs were produced. An expression plasmid that was previously used for the expression, purification and characterisation of an N-terminally His-tagged EcRNase E NTD 19, 29 was obtained from Prof. Ben Luisi, University of Cambridge, UK. We adopted a similar cloning strategy for YpRNase E, FtRNase E, BpRNase E and AbRNase E NTDs. All five RNase E NTDs were expressed as N-terminally His-tagged proteins and purified by immobilised Ni 2+ -affinity chromatography, followed by size-exclusion chromatography, as described previously for EcRNase E NTD 19 . All five RNase E NTDs were successfully purified using this approach ( Supplementary Fig. S3 ).
Low-resolution solution structure of RNase e NtDs. The catalytically active form of EcRNase E NTD has been shown to be homotetrameric in solution 19 . During purification, YpRNase E, FtRNase E, BpRNase E and AbRNase E NTDs all eluted from the size-exclusion column at a similar volume to EcRNase E NTD ( Supplementary Table S1 ), which would be consistent with them also forming homotetramers. In order to further investigate, and compare, the structures of the RNase E NTDs, SAXS was employed. SAXS is a technique that is able to provide low resolution structural information about the size and shape of proteins in solution 30 . Parameters including molecular weight, radius of gyration (R g ), which indicates the overall size of the protein, and maximum particle dimension (D max ) can be derived from the scattering data, along with information about protein flexibility 30 . The scattering data for the RNase E NTDs are presented in Fig. 3a . Molecular masses were estimated from the SAXS profiles ( Supplementary Table S1 ) and are consistent with each protein forming a tetramer in solution. For each RNase E NTD, the R g was determined from Guinier analysis ( Fig. 3aii ). R g s ranged from 48 to 51 Å, indicating that all five RNase E NTDs are a similar overall size. The D max was determined from the pair distance distribution (p(R)) plot (Fig. 3b ), a plot of the distances between all possible pairs of atoms within the protien 30 , and ranged from 149 to 183 Å, suggesting some variability in the degree of extension of the proteins. Finally, dimensionless Kratky plots were used to assess the folding state and flexibility of the proteins 30 . The Kratky plots ( Fig. 3c ) were similar for each RNase E NTD and had the characteristic multiple bell-shaped profile of a multi-domain globular protein.
Ab initio models for EcRNase E NTD were generated based on the SAXS data and were compared to three available EcRNase E NTD crystal structures, 2BX2 (closed conformation) 18 , 2VMK (open conformation) 26 and 5F6C (a transitioning conformation) 25 ( Supplementary Fig. S4a ). None of the crystal structures could be fitted entirely within the average molecular envelope. The experimental scattering data for EcRNase E NTD was also compared to theoretical scattering data for the three crystal structures ( Supplementary Fig. S4b ). We compared the resulting χ 2 values to evaluate which of the crystallised conformations the solution scattering data most closely resembles. For EcRNase E NTD, the data are most consistent with the transitioning conformation (Supplementary Table 2 ; Supplementary Fig. S4b ). A similar comparison of the experimental scattering data for YpRNase E, FtRNase E, BpRNase E and AbRNase E NTDs to the theoretical scattering data for the three EcRNase E crystal structures was also performed. This revealed that, in solution, YpRNase E, FtRNase E and AbRNase E www.nature.com/scientificreports www.nature.com/scientificreports/ also most closely resemble the transitioning EcRNase E NTD conformation ( Supplementary Table S2 ). In contrast, BpRNase E most closely resembles the closed EcRNase E NTD conformation ( Supplementary Table S2 ). endoribonuclease Activity of RNase e NtDs. Having established that EcRNase E, YpRNase E, FtRNase E, BpRNase E and AbRNase E NTDs are all homotetramers that adopt similar global conformations in solution, we next wanted to investigate their catalytic properties. We decided to assess the endoribonuclease activity of each of the RNase E NTDs using a model 5′ p-RNA13-FAM-3′ substrate in a discontinuous end-point assay ( Fig. 4 ). RNA13 has the same nucleotide sequence as the 13-mer oligoribonucleotide that was crystallised in complex with EcRNase E NTD 18 and is based on a known EcRNase E cleavage site within RNAI from the pBR322 plasmid 31 . Endoribonucleolytic cleavage is expected to occur between the 8 th and 9 th nucleotide from the 5′ end of the substrate to generate an unlabelled octamer and a 3′ FAM-labelled pentamer ( Fig. 4 ). Both the disappearance of the 3′ FAM-labelled 13-mer substrate and the appearance of the 3′ FAM-labelled pentamer product can be monitored by denaturing polyacrylamide gel electrophoresis (PAGE). As expected, EcRNase E NTD efficiently cleaved this substrate such that 95% of the substrate had been degraded at the assay end-point ( Fig. 4) . YpRNase E, FtRNase E, BpRNase E and AbRNase E NTDs also endoribonucleolytically cleaved 5′ p-RNA13-FAM-3′ (Fig. 4 ). The cleavage 18 and open (2VMK) 26 conformations of E. coli RNase E NTD (blue ribbons) and homology models of Y. pestis, F. tularensis, B. pseudomallei and A. baumannii RNase E NTDs (various coloured ribbons). The Mg 2+ ions are shown as magenta spheres and the Zn 2+ ions are shown as cyan spheres. The averaged homology models have been overlaid with the E. coli RNase E NTD crystal structure that was used as the template. The RMSD for each homology model in comparison with the template structure is reported in the top left-hand corner of the homology model panel. baumannii RNase E NTD were incubated with 1 μM 5′-p-RNA13-FAM-3′ (p-RNA13) or 1 μM 5′-OH-RNA13-FAM-3′ (OH-RNA13) at 28 °C for 45 minutes. Reaction products were resolved by 20% urea-PAGE and visualised using a G:Box UV transilluminator (Syngene). This figure is assembled from multiple gels that have been cropped. The uncropped gels are presented in Supplementary Fig. S5 . The percentage of cleaved RNA present in each lane is indicated below the gels. Values are an average of three experiments, values have been rounded to the nearest whole numbers. Errors, where given, are the standard deviation to the nearest whole number ( a calculated error was below 0.5).
www.nature.com/scientificreports www.nature.com/scientificreports/ efficiency for YpRNase and FtRNase E NTDs was similar to EcRNase E NTD (96% and 93% of the substrate had been degraded at the assay end-point, respectively). However, BpRNase E and AbRNase E NTDs both cleaved 5′ p-RNA13-FAM-3′ less efficiently than EcRNase E NTD (58% and 88% of the substrate had been degraded at the assay end-point, respectively).
Substrate specificity of RNase E NTDs.
EcRNase E is known to have a strong preference for substrates with a 5′ monophosphate 23 (e.g. 5′ p-RNA13-FAM-3′). In order to investigate whether YpRNase E, FtRNase E, BpRNase E and AbRNase E NTDs also share this preference we decided to compare the degradation of a 5′-OH-RNA13-FAM-3′, which has a 5′ hydroxyl, and 5′-p-RNA13-FAM-3′ in the discontinuous end-point assay (Fig. 4 ). As discussed above, EcRNase E NTD efficiently cleaved the 5′-p-RNA13-FAM-3′ substrate with 95% substrate degraded at the assay end-point. However, as expected, cleavage of the 5′-OH-RNA13-FAM-3′ substrate was relatively inefficient and only 10% of this substrate was degraded by EcRNase E NTD by the assay end-point. Similarly, compared to 5′ p-RNA13-FAM-3′, 5′-OH-RNA13-FAM-3′ was a poor substrate for YpRNase E, FtRNase E, BpRNase E and AbRNase E NTDs. However, while EcRNase E, YpRNase E, BpRNase E and AbRNase E NTDs degraded 10% or less of the 5′-OH-RNA13-FAM-3′ by the assay end-point, FtRNase E NTD cleaved 25% of this substrate, 2.5-fold more than any of the other RNase E NTDs. Therefore, while all five RNase E NTDs display a preference for 5′ monophosphorylated substrates, this preference is less pronounced for FtRNase E.
The short 5′-p-RNA13-FAM-3′ model substrate is cleaved by all of the RNase E NTDs at a specific, single site. However, longer, more complex substrates have the potential to be cleaved at multiple sites. For example, a partially double-stranded target-guide substrate consisting of a 5′ DABCYL-labelled, 3′ FAM-labelled 27-mer and a 5′ phosphorylated 13-mer with partial complementarity to the 5′ end of the 27-mer ( Fig. 5ai ) is known to be cleaved by EcRNase E NTD at multiple sites, each with a different susceptibility to EcRNase E 32 . Therefore, we decided to use the target-guide substrate in a discontinuous assay to compare cleave site specificity of the RNase E NTDs. In an initial experiment, 5 nM RNase E NTD was incubated with 1 μM target-guide RNA at 28 °C and the cleavage products were analysed by denaturing PAGE after 10 minutes (Fig. 5aii) . EcRNase E NTD cleaved the 27-mer component of the target-guide substrate at five positions: between nucleotides 15 and 16, 16 and 17, 19 and 20, 22 and 23 and 24 and 25, from the 5′ end, to generate 3′ FAM-labelled cleavage products 12, 11, eight, five and three nucleotides in length, respectively. Similar cleavage patterns were observed for YpRNase E, BpRNase E and AbRNase E NTDs. Each of these RNase E NTDs also cleaved the 27-mer RNA at the positions cleaved by EcRNase E NTD. Although additional cleavage sites were detected between nucleotides 17 and 18 for AbRNase E NTD, generating a 3′ FAM-labelled product ten nucleotides in length, and between nucleotides 23 and 24 for YpRNase E NTD, generating a 3′ FAM-labelled product four nucleotides in length. The relative predominance of the bands representing the common cleavage sites were also similar for EcRNase E, YpRNase E, BpRNase E and AbRNase E NTDs. In contrast, FtRNase E NTD displayed a markedly different cleavage pattern to the other four RNase E NTDs. In addition to cleaving the 27-mer RNA at the five positions that are cleaved by the other RNase E NTDs, FtRNase E NTD also cleaved the 27-mer RNA between nucleotides 18 and 19 and between nucleotides 21 and 22, generating 3′ FAM-labelled products nine and six nucleotides in length, respectively. Furthermore, the relative predominance of the bands representing the common cleavage sites was different for FtRNase E NTD relative to the other four RNase E NTDs.
Given the observed similarities and differences in the cleavage patterns of the RNase E NTDs, time-course experiments were then used to identify initial cleavage sites and/or preferred cleavage sites (Fig. 5b ). For EcRNase E NTD, all five cleavage products began to appear from the start of the time-course, consistent with a distribution of single cleavage events. The octamer accumulated at the fastest rate, closely followed by the 12-and 11-mers suggesting that the preferred cleavage site is between nucleotides 19 and 20, from the 5′ end of the 27-mer. A similar accumulation of products was observed for YpRNase E, BpRNase E and AbRNase E NTDs except that the 11-mer and the 12-mer accumulated at the fastest rate for BpRNase E and AbRNase E NTDs, respectively. For FtRNase E NTD, the 12-mer accumulated significantly faster than the other cleavage products indicating that the preferred cleavage site is between nucleotides 15 and 16. Interestingly, after three minutes, the abundance of this cleavage product began to decline while the abundance of the trimer, pentamer and hexamer dramatically increased. This suggests that the initial 12-mer product can undergo a secondary cleavage to produce the shorter trimers, pentamers and hexamers.
Discussion
We have investigated the structural and biochemical properties of the NTD of four, previously uncharacterised, RNase E homologues from bacterial pathogens and compared them to those of the well-characterised NTD from E. coli RNase E. Fundamentally, these NTDs are highly conserved at the sequence level and, as might have been expected, they have similar properties in that they are all homotetrameric, endoribonucleases. However, there are also subtle differences between them. The NTD from RNase E from B. pseudomallei is predicted to adopt a more closed conformation than the other RNase E NTDs ( Fig. 3 and Supplementary Table S2 ) while the substrate specificity of F. tularensis RNase E NTD differs from the other RNase E NTDs (Figs 4 and 5) .
Three principle regions of sequence variability were identified in the RNase E NTDs, amino acids 175-203, 233-263 and 457-508 ( Fig. 1 ). Despite this sequence variability, the structure of these regions is predicted to be conserved (Figs 2 and S2 ). Two of these regions, one in the 5′ sensor domain (amino acids 175-203) and one in the RNase H domain (amino acids 233-263), are located at the peripheral edges of the tetrameric protein structure ( Supplementary Fig. S2 ). These regions have no known direct catalytic function; however, given their location, it is possible that they may play a structural role in the movement of the 5′ sensor and S1 domains during the transition from an open to a closed conformation upon substrate binding. Interestingly, in solution, the RNase E NTD from B. pseudomallei adopts a more closed conformation than the other four RNase E NTDs ( Fig. 3 and Supplementary Table S2 ) which could be related to the divergent sequence in this region. The third region of Coloured arrows indicate the position of cleavage sites that were observed for at least one of the RNase E NTDs, with the numbers above the arrows indicating the length of the 3′ FAM-labelled product that is produced by cleavage at that position. The cleavage sites that were observed for each homologue are indicated by stars above the respective position. (aii) 20% urea-PAGE analysis of cleavage of 1 μM target-guide substrate by 5 nM E. coli, Y. pestis, F. tularensis, B. pseudomallei or A. baumannii RNase E NTD after incubation at 28 °C for 10 minutes. The gel was visualised using a G:Box UV transilluminator (Syngene). The gel in this figure has been cropped and the uncropped gel is presented in Supplementary Fig. S6a . The band corresponding to the FAM-labelled 27-mer component of the target-guide substrate is labelled and the coloured arrows to the right of the gel correspond to the FAM-labelled cleavage products described in ai. (b) 20% urea-PAGE analysis of cleavage of 1 μM targetguide substrate by 5 nM E. coli, Y. pestis, F. tularensis, B. pseudomallei or A. baumannii RNase E NTD at 28 °C during a 10-minute time course. Gels were visualised using a G:Box UV transilluminator. The gels have been sequence variability, in the small domain (amino acids 457-508), is located at the protomer-promoter interface ( Supplementary Fig. S2) , where amino acid substitutions could affect tetramerisation. However, all five RNase E NTDs appear to be homotetrameric in solution ( Supplementary Table S1 ), suggesting that the function of the small domain is conserved.
All of the RNase E NTDs investigated endoribonucleolytically cleaved model RNA substrates (Figs 4 and 5 ). This was not surprising given that the key residues known to be involved in RNA cleavage at the active site are absolutely conserved (Fig. 1) . This study utilised model RNA substrates that we would expect to be cleaved via a 5′ end-dependent mechanism in which a 5′ monophosphate is specifically recognised by the 5′ sensor pocket 18, 23, 31 .
The key residues known to be required for discriminating substrates with a 5′ monophosphate within this pocket are absolutely conserved in the RNase E NTDs investigated and, not surprisingly, all of the RNase E NTDs showed a preference for a 5′ monophosphorylated substrate (Fig. 4 ). However, more complex natural substrates such as 9S RNA, the precursor of 5S rRNA, can also be cleaved through an internal entry mechanism which relies on the recognition of a stem loop structure upstream of the cleavage site [33] [34] [35] . A recent study identified eight amino acids (Arg 3 , Gln 22 , His 268 , Tyr 269 , Gln 270 , Lys 433 , Arg 488 and Arg 490 ) in the E. coli RNase E NTD domain that are important for recognition of the stem loop 25 . These residues are absolutely conserved in Y. pestis RNase E but there are substitutions at two of the positions in B. pseudomallei and at six of the positions in F. tularensis and A. baumannii RNase Es. It remains to be seen whether these substitutions affect RNA cleavage through the internal entry mechanism for these RNase Es. Finally, substrate cleavage patterns varied between the RNase E NTDs, with the most striking differences observed for F. tularensis RNase E (Fig. 5 ), hinting at possible differences in the reaction mechanism.
In conclusion, we have characterised the RNase E NTD homologues from Y. pestis, F. tularensis, A. baumannii and B. pseudomallei. This is the first demonstration that these RNase E NTDs have endoriboucleolytic activity. Furthermore, through a comparison with EcRNase E NTD, we have shown that, despite the expected global structural and catalytic similarities, there are also subtle species-specific differences between them. These observed subtle differences would not have been predicted de novo from amino acid sequence. The most significant differences were identified in two of the RNase E NTDs with the lowest sequence similarity, B. pseudomallei and F. tularensis. However, B. pseudomallei RNase E NTD varied in its structural properties while F. tularensis RNase E NTD varied in its biochemical properties. It remains to be determined, how significant these differences prove to be, but it does suggest caution when applying generalities based on studies with model organisms. In terms of the development of antibacterial drugs targeting RNase E, it has already been reported that RNase Es from different species respond differently to compounds selected based on inhibition of RNase E from E. coli 13 . Therefore, these subtle differences may prove to be critical when designing antibacterial approaches targeting RNase E in pathogens.
Methods protein sequence alignment. RNase E amino acid sequences were downloaded from UniProtKB using the following accession codes: EcRNase E (P21513), YpRNase E (Q74TC3), FtRNase E (Q5NFK7), BpRNase E (A0A0H3HN63) and AbRNase E (A0A0B9WR03). The sequences were aligned in MOE (Molecular Operating Environment, 2013.08; Chemical Computing Group Inc., 1010 Sherbrooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7) using the default parameters, including a BLOSUM62 substitution matrix. This alignment was used to define the catalytic NTD for each of the RNase Es as the amino acids that aligned with amino acids 1-529 of EcRNase E. Sequences were then trimmed to the NTD boundaries and the similarity of each homologue to EcRNase E NTD was calculated in MOE.
RNase e NtD homology models. RNase E NTD homology models were generated for YpRNase E, FtRNase E, BpRNase E and AbRNase E in MOE using the sequences that had been trimmed to the NTD boundaries ( Fig. 1) , EcRNase E NTD crystal structures as the template structure (2BX2 18 for the closed conformation and 2VMK 26 for the open conformation) and the default settings. Ten initial modes were produced and averaged to give the most energetically favourable model. The RMSD between each model and the template EcRNase E NTD structure was calculated in MOE.
Cloning of RNase e NtD expression strains.
RNase E NTDs were cloned into the pET16b expression plasmid (Novagen), in order to express them as N-terminally His 10 -tagged proteins. EcRNase E NTD (aa 1-529) cloned into pET16b, was kindly provided by Prof. Ben Luisi (University of Cambridge, UK). The coding sequences for the RNase E NTDs were obtained from the European Nucleotide Archive: YpRNase E (aa 1-529; CAL20235.1), FtRNase E (aa 1-543; KFJ71366.1), BpRNase E (aa 1-532; EET07304.1), and AbRNase E (aa 1-544; A0A0B9WR03). The genes were codon-optimised in silico using GeneOtimizer ® software (GeneArt, Life Technologies), synthesised by GeneArt and ligated between the NdeI and BamHI restriction sites of pET16b. All constructs were confirmed by DNA sequencing and E. coli BL21(DE3)pLysS was transformed with the plasmids for protein expression. cropped and the uncropped gels are presented in Supplementary Fig. S6b . Coloured arrows to the right of the gels correspond to the cleavage positions depicted in ai. www.nature.com/scientificreports www.nature.com/scientificreports/ protein expression. RNase E NTD expression strains were grown in 500 ml LB supplemented with 100 μg/ ml ampicillin, at 37 °C, with shaking (250 rpm), until the OD 600 reached 0.6. Recombinant protein expression was induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM and cells were incubated for a further 3 hours, at 37 °C, with shaking. Cells were harvested by centrifugation at 7,000 rcf and 4 °C for 20 minutes and stored at −20 °C.
Protein purification.
All RNase E NTDs were purified essentially as described previously for EcRNase E NTD 19 . Briefly, frozen cell pellets were thawed on ice and resuspended in 50 ml of lysis buffer (20 mM Tris-HCl pH 8, 500 mM NaCl and 20 mM imidazole) supplemented with a cOmplete TM ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor cocktail tablet (Roche). Cells were lysed by sonication for 10 minutes (3.3 seconds on, 9.9 seconds off) using a Sonics Vibra Cell VCX 500 sonicator. Each lysate was clarified by centrifugation at 40,000 g, at 4 °C, for 20 minutes and was subsequently loaded onto a 5 ml HisTrap FF column (GE Healthcare) equilibrated in lysis buffer using an ÄKTA Purifier (GE Healthcare). Bound proteins were eluted with a linear gradient from 20 to 500 mM imidazole (0 to 100% elution buffer (20 mM Tris pH 8, 500 mM NaCl and 500 mM imidazole)) applied over six column-volumes. Fractions containing RNase E NTD were pooled and buffer-exchanged into storage buffer (20 mM Tris 
size-exclusion chromatography coupled small-angle x-ray scattering (seC-sAXs). SEC-SAXS
experiments were performed at the B21 beamline at the Diamond Light Source (DLS, Didcot, UK). RNase E NTDs were concentrated using a Vivaspin 20 (MWCO 10 kDa) centrifugal concentrator to a concentration of 5-10 mg/ml in sample buffer (10 mM DTT, 10 mM MgCl 2 , 0.5 M NaCl, 20 mM Tris (pH 8)). 45 μl were loaded onto a 4.6 ml KW403-4F size-exclusion column (Showdex) equilibrated in sample buffer at a flow rate of 0.1 ml/ min, using an Agilent 1260 HPLC system. SAXS data were collected at 3-second intervals, at a wavelength of 12.4 KeV and a fixed camera length of 4.014 m using a Pilatus 2 M photon counting detector (Dectris), for 32 minutes. The data were normalised to the intensity of the incident beam and the scattering from the buffer was subtracted using an in-house program. Further data processing was then performed with the ATSAS suite 36 . PRIMUS 37 was used to calculate the R g and forward scattering intensity (I(0)) for the RNase E NTDs. I(0) was used to calculate the molecular weight (MW). The distance distribution function p(R) was generated with GNOM 38 and was used to determine the D max . For EcRNase E NTD 20 ab initio models were generated in DAMMIF 39 and averaged in DAMAVER 40 . Crystal structures for EcRNase E NTD in a closed conformation (2BX2; 18 ), open conformation (2VMK; 26 ) and a transitioning conformation (5F6C; 25 ) were fitted to the averaged model using CHIMERA 41 . The theoretical scattering, based on the crystal structures, for EcRNase E NTD in each of these three conformations was compared to the experimental scattering for each RNase E NTD in CRYSOL 42 .
RNase e discontinuous assay. Discontinuous RNase E assays were carried out using one of three model RNA substrates: 5′ phosphorylated, 3′ FAM-labelled UUU ACA GUA UUU G (5′-p-RNA13-FAM-3′) 13-mer 18, 31 ; 5′ hydroxylated, 3′ FAM-labelled UUU ACA GUA UUU G (5′-OH-RNA13-FAM-3′) 13-mer or a partially double-stranded substrate (target-guide; 32 ) generated by annealing a 5′ 4-(4-dimethylaminophenyl) diazenylbenzoic acid (DABCYL)-labelled, 3′ FAM-labelled GGA UCG GAG UUU UAA AUU AAU AAU AUA 27-mer and a 5′ phosphorylated UUU UCU CCG AUC C 13-mer at 28 °C for 15 minutes. The labelled 27-mer and unlabeled 13-mer were annealed at a ratio of 1:1.14 to ensure that all of the labelled 27-mer was partially double-stranded. All RNAs were obtained from Dharmacon. 30 μl reaction mixtures containing 1.25 to 5 nM RNase E NTD (see Figure legends for details), 1 μM substrate (see Figure legends for details), 25 mM Tris pH 8, 100 mM NaCl, 15 mM MgCl 2 , 1 mM DTT, 37.5 mg/ml Ficoll 70 and 5% (v/v) dimethyl sulfoxide (DMSO) were incubated at 28 °C for the indicated time(s). Reactions were terminated by the addition of 0.5 volumes of quench buffer (95% (v/v) formamide, 20 mM EDTA) and reaction products were resolved by denaturing 7.5 M urea 20% PAGE. Gels were visualised using a G:Box UV transilluminator (Syngene) and, where indicated, quantified by densitometry using ImageJ (Rasband WS, ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2016).
